LineaRx Ships DNA to Support Therapy Development for Neurodegenerative Diseases
June 26 2019 - 9:15AM
Business Wire
Interest in large-scale Linear DNA for nucleic
acid-based therapies continues to rise
LineaRx, Inc. a wholly-owned subsidiary of Applied DNA Sciences,
Inc. (NASDAQ: APDN), announced today that it has shipped multiple
customized linear DNA amplicons to Evotec SE, a well-known
therapeutic development company, to support their research efforts
related to neurodegenerative diseases such as Huntington’s,
Parkinson’s or Alzheimer’s disease. DNA amplicons are segments of
DNA that can serve as templates to generate the RNA or more DNA
necessary for nucleic acid-based therapies.
“LineaRx collaborated closely with the customer on the design,
production and post processing of their unique amplicon
specifications,” stated Dr. James Hayward, president and CEO of
LineaRx. “Evotec SE, like a growing number of other cutting-edge
biotech companies, sees value in evaluating linear DNA as a
foundation for their research and recognizes the strengths of
LineaRx in the design and large-scale production of linear DNA
using LineaRx’s proprietary platform for DNA production by
polymerase chain reaction (“PCR”). The amplicons will be evaluated
by Evotec SE over the next few months.”
Our shipment to Evotec SE, in support of neurodegenerative
disease therapy research, is representative of a growing number of
therapy developers coming to LineaRx and placing research quantity
orders to evaluate the benefits of linear DNA in their therapeutic
development pipeline. Many of the disease targets would have been
considered unapproachable by gene therapies only a short time
ago.
“Our expertise in PCR, as well as our pathway to cGMP large
scale production, makes LineaRx a valuable partner to those
companies pursuing a plasmid-free path,” indicated Brian Viscount,
Director of LineaRx. “We continue to see growing demand for linear
DNA, in both double-stranded and single-stranded formats, across a
wide variety of nucleic acid-based therapies. We have the research
bandwidth and production capacity to respond to the increasing
demand we are seeing.”
About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of
Applied DNA Sciences’ deep expertise and experience in the design,
manufacture and chemical modification of DNA by large scale
polymerase chain reaction (“PCR”). Linear DNA is a form of DNA
distinct from the circular form of DNA most commonly produced in
plasmids and grown in bacteria. Plasmids are extrachromosomal DNA
found in bacteria and are associated with the genes for antibiotic
resistance which are often exchanged between bacteria and
consequentially, are seen by many to embody a serious threat to
global health. In addition, many nucleic acid-based therapies also
rely on viral vectors for efficient transfection and expression of
plasmid DNA. These viral vectors carry additional nontrivial risks
and are extremely time consuming and expensive to manufacture.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to its history of net losses, limited financial
resources, limited market acceptance , the uncertainties inherent
in research and development, future clinical data and analysis,
including whether any of Applied DNA’s product candidates will
advance further in the preclinical research or clinical trial
process, including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive
final approval from the U.S. FDA or equivalent foreign regulatory
agencies, the uncertainly relating to its ability to maintain its
NASDAQ listing and various other factors detailed from time to time
in Applied DNA’s SEC reports and filings, including our Annual
Report on Form 10-K filed on December 18, 2018 and our subsequent
quarterly reports on Form 10-Q filed on February 7, 2019 and May 9,
2019, and other reports we file with the SEC, which are available
at www.sec.gov. Applied DNA undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
web: www.adnas.com twitter: @APDN, @LineaRxDNA
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190626005160/en/
Investors: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com Program: Brian Viscount,
631-240-8877, brian.viscount@adnas.com
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024